FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Provided By GlobeNewswire
Last update: Jul 29, 2025
NASDAQ:APLS (10/31/2025, 11:51:09 AM)
20.425
-0.3 (-1.47%)
Find more stocks in the Stock Screener
APLS Latest News and Analysis
a day ago - By: Chartmill
